Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Alkem-Laboratories"

29 News Found

Diversification by pharma companies critical to repositioning supply chain
News | March 02, 2022

Diversification by pharma companies critical to repositioning supply chain

Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel


Alkem enters exclusive license agreement with Johns Hopkins University
Healthcare | January 31, 2022

Alkem enters exclusive license agreement with Johns Hopkins University

The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer


Alkem Labs to launch treatment for Diabetic Foot Ulcer
News | January 12, 2022

Alkem Labs to launch treatment for Diabetic Foot Ulcer

This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates


DCGI approves Enzene biosimilar Denosumab for Osteoporosis
Drug Approval | August 28, 2021

DCGI approves Enzene biosimilar Denosumab for Osteoporosis

This is Enzene Biosciences third biosimilar to be approved


Enzene Biosciences obtains DCGI approval for Romiplostim biosimilar
Biotech | August 20, 2021

Enzene Biosciences obtains DCGI approval for Romiplostim biosimilar

It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)


Alkem launches Ibuprofen and Famotidine tablets in US
News | August 07, 2021

Alkem launches Ibuprofen and Famotidine tablets in US

Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg


Alkem launch two drugs in US
News | August 04, 2021

Alkem launch two drugs in US

Ibuprofen and Famotidine tablets approved by FDA


Alkem launches Perampil tablets at affordable prices
News | June 11, 2021

Alkem launches Perampil tablets at affordable prices

The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access


Alkem Q4FY21 consolidated PAT drops QoQ to Rs. 239.99 Cr
News | May 25, 2021

Alkem Q4FY21 consolidated PAT drops QoQ to Rs. 239.99 Cr

It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.